Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Immunic, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 10.35 · gapped above the open, then crossed back over prior close. High/low 11.19 at 5:15 am ET, 10.33 at 3:30 pm ET.
Immunic, Inc. has 16 disclosed suppliers and 0 disclosed customers. Each one is named in an SEC filing, either Immunic, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
No filing we have read names a customer of Immunic, Inc.. Customers appear here when Immunic, Inc. names them, or when a company names Immunic, Inc. as a supplier in its own annual report.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“On March 31, 2021, Immunic AG and 4SC entered into a Settlement Agreement, pursuant to which Immunic AG settled its remaining obligation of a 4.4% royalty on net sales for $17.25 million.”
FILING10-K0001280776-26-000005cik 0001280776
“Leerink Partners LLC acted as lead placement agent for the Offering, Stifel, Guggenheim Securities, William Blair, LifeSci Capital, B. Riley Securities and Brookline Capital Markets, a division of Arcadia Securities, LLC also acted as placement agents for the February 2026 Offering.”
FILING10-K0001280776-26-000005cik 0001280776
“Leerink Partners LLC acted as lead placement agent for the Offering, Stifel, Guggenheim Securities, William Blair, LifeSci Capital, B. Riley Securities and Brookline Capital Markets, a division of Arcadia Securities, LLC also acted as placement agents for the February 2026 Offering.”
FILING10-K0001280776-26-000005cik 0001280776
“On February 12, 2026, the Company entered into a purchase and sale agreement (the "Royalty Purchase Agreement") with certain Series B Warrant holders who had purchased a predetermined number of Series B Warrants (each a "Participating Series B Holder") and BVF Partners, L.P. ("BVF"), acting as royalty interest agent (the "Warrant Exchange").”
FILING10-K0001280776-26-000005cik 0001280776
“For instance, in November 2018, Immunic AG and Daiichi Sankyo entered into a license and option agreement that grants us an exclusive global option to license IMU-856 and related molecules.”
FILING10-K0001280776-26-000005cik 0001280776
“Leerink Partners LLC acted as lead placement agent for the Offering, Stifel, Guggenheim Securities, William Blair, LifeSci Capital, B. Riley Securities and Brookline Capital Markets, a division of Arcadia Securities, LLC also acted as placement agents for the February 2026 Offering.”
FILING10-K0001280776-26-000005cik 0001280776
“Leerink Partners LLC acted as lead placement agent for the Offering, Stifel, Guggenheim Securities, William Blair, LifeSci Capital, B. Riley Securities and Brookline Capital Markets, a division of Arcadia Securities, LLC also acted as placement agents for the February 2026 Offering.”
FILING10-K0001280776-26-000005cik 0001280776
“Leerink Partners LLC acted as lead placement agent for the Offering, Stifel, Guggenheim Securities, William Blair, LifeSci Capital, B. Riley Securities and Brookline Capital Markets, a division of Arcadia Securities, LLC also acted as placement agents for the February 2026 Offering.”
FILING10-K0001280776-26-000005cik 0001280776
“In addition, on April 9, 2025, the Company entered into a placement agency agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC (the "Placement Agent"), relating to the April 2025 Offering.”
FILING10-K0001280776-26-000005cik 0001280776
“Leerink Partners LLC acted as lead placement agent for the Offering, Stifel, Guggenheim Securities, William Blair, LifeSci Capital, B. Riley Securities and Brookline Capital Markets, a division of Arcadia Securities, LLC also acted as placement agents for the February 2026 Offering.”
FILING10-K0001280776-26-000005cik 0001280776
“We also conduct preclinical work in our laboratory in Martinsried, Germany and in Halle/Saale, Germany and through a collaboration with the Fraunhofer Institute.”
FILING10-K0001280776-26-000005cik 0001280776
“The increase was primarily attributable to (i) $4.8 million of grant income from the German Federal Ministry of Finance, of which $1 million was recognized in the first quarter 2025 and $3.8 million was recognized in the fourth quarter 2025, (ii) a $1.7 million expense related to the portion of deal costs from the January 2024 Financing related to the tranche rights that were established at the time of the deal closing in 2024 and (iii) a $0.3 million increase across numerous categories.”
FILING10-K0001280776-26-000005cik 0001280776
“In addition, we have entered into an at-the-market sales agreements with Leerink Partners LLC ("Leerink Partners"), which provides that we may offer and sell from time to time through Leerink Partners as sales agent, up to $80 million of common stock in "at the market offerings" (as defined in Rule 415 under the Securities Act of 1933, as amended)).”
FILING10-K0001280776-26-000005cik 0001280776
“On January 5, 2026, we were notified by the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that our application to transfer the listing of our Common Stock from the Nasdaq Global Select Market to the Nasdaq Capital Market had been approved (the "Approval").”
FILING10-K0001280776-26-000005cik 0001280776
“On September 9, 2025, we announced that we received a Notice of Allowance from the United States Patent and Trademark Office ("USPTO") for patent application 18/529,946, entitled "Treatment of multiple sclerosis comprising DHODH inhibitors."”
FILING10-K0001280776-26-000005cik 0001280776
“Other Commitments and Obligations See Note 2 - Collaboration Arrangements of the Notes to the Financial Statements regarding the Company's obligations under the option agreement with Daiichi Sankyo, which includes the potential payment of future development, regulatory and sales milestone payments, as well as royalties related to IMU-856 and the Ludwig-Maximilians-University Agreements where the Ludwig-Maximilians-University is entitled to receive future development, regulatory and sales milestone payments related to these molecules.”
FILING10-K0001280776-26-000005cik 0001280776
Watchlist prices, news filtered to it, and its next report on your desk.
IMUX (Immunic, Inc.) has 16 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move, and a bundle sits past the rings until you open it. Extended: satellites hang off single companies, not bundled sectors.